{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T04:07:43Z","timestamp":1792123663756,"version":"4.4.0"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["ajo.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.ajo.2024.12.028","type":"journal-article","created":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T20:46:27Z","timestamp":1735937187000},"page":"8-18","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Pathogenic Mechanisms of Immune Checkpoint Inhibitor (ICI)-Associated Retinal and Choroidal Adverse Reactions"],"prefix":"10.1016","volume":"272","author":[{"given":"Rachana","family":"Haliyur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan G.","family":"Elner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Therese","family":"Sassalos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilpa","family":"Kodati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9720-8761","authenticated-orcid":false,"given":"Mark W.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ajo.2024.12.028_bib0001","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"New Engl J Med"},{"issue":"7","key":"10.1016\/j.ajo.2024.12.028_bib0002","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s40265-021-01507-z","article-title":"Ocular toxicity of targeted anticancer agents","volume":"81","author":"Fortes","year":"2021","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.ajo.2024.12.028_bib0003","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1097\/IAE.0000000000002181","article-title":"Checkpoint inhibitor immune therapy","volume":"38","author":"Dalvin","year":"2018","journal-title":"Retin"},{"issue":"9","key":"10.1016\/j.ajo.2024.12.028_bib0004","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1136\/bjophthalmol-2020-316970","article-title":"Ophthalmic adverse effects of immune checkpoint inhibitors: the Mayo Clinic experience","volume":"105","author":"Fortes","year":"2021","journal-title":"Brit J Ophthalmol"},{"issue":"12","key":"10.1016\/j.ajo.2024.12.028_bib0005","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1007\/s00262-020-02635-3","article-title":"Factors associated with ocular adverse event after immune checkpoint inhibitor treatment","volume":"69","author":"Kim","year":"2020","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"10.1016\/j.ajo.2024.12.028_bib0006","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12348-022-00321-2","article-title":"Ocular adverse events associated with immune checkpoint inhibitors, a scoping review","volume":"13","author":"Martens","year":"2023","journal-title":"J Ophthalmic Inflamm Infect"},{"issue":"14","key":"10.1016\/j.ajo.2024.12.028_bib0007","doi-asserted-by":"crossref","first-page":"3426","DOI":"10.3390\/cancers13143426","article-title":"Poor response to checkpoint immunotherapy in Uveal melanoma highlights the persistent need for innovative regional therapy approaches to manage liver metastases","volume":"13","author":"Szeligo","year":"2021","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.ajo.2024.12.028_bib0008","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s40123-024-00913-2","article-title":"The future of checkpoint inhibitors in Uveal melanoma: a narrative review","volume":"13","author":"Wang","year":"2024","journal-title":"Ophthalmol Ther"},{"issue":"3","key":"10.1016\/j.ajo.2024.12.028_bib0009","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0150945","article-title":"T-lymphocytes traffic into the brain across the blood-CSF barrier: evidence using a reconstituted choroid plexus epithelium","volume":"11","author":"Strazielle","year":"2016","journal-title":"PLoS ONE"},{"issue":"3","key":"10.1016\/j.ajo.2024.12.028_bib0010","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00401-018-1807-1","article-title":"Molecular anatomy and functions of the choroidal blood-cerebrospinal fluid barrier in health and disease","volume":"135","author":"Ghersi-Egea","year":"2018","journal-title":"Acta Neuropathol"},{"issue":"6","key":"10.1016\/j.ajo.2024.12.028_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2024.100539","article-title":"Liquid biopsy for proliferative diabetic retinopathy: single-cell transcriptomics of human vitreous reveals inflammatory T-cell signature","volume":"4","author":"Haliyur","year":"2024","journal-title":"Ophthalmol Sci"},{"issue":"2","key":"10.1016\/j.ajo.2024.12.028_bib0012","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1076\/ocii.11.2.91.15914","article-title":"Participation of pigment epithelium in ocular immune privilege. 3. Epithelia cultured from iris, ciliary body, and retina suppress T-cell activation by partially non-overlapping mechanisms","volume":"11","author":"Ishida","year":"2003","journal-title":"Ocul Immunol Inflamm"},{"issue":"6","key":"10.1016\/j.ajo.2024.12.028_bib0013","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/j.exer.2006.08.005","article-title":"Retinal and ciliary body pigment epithelium suppress activation of T lymphocytes via transforming growth factor beta","volume":"83","author":"Sugita","year":"2006","journal-title":"Exp Eye Res"},{"issue":"11","key":"10.1016\/j.ajo.2024.12.028_bib0014","doi-asserted-by":"crossref","first-page":"7525","DOI":"10.4049\/jimmunol.181.11.7525","article-title":"Retinal pigment epithelium-derived CTLA-2\u03b1 induces TGF\u03b2-producing T regulatory cells","volume":"181","author":"Sugita","year":"2008","journal-title":"J Immunol"},{"issue":"6","key":"10.1016\/j.ajo.2024.12.028_bib0015","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1167\/iovs.08-2846","article-title":"T-cell suppression by programmed cell death 1 ligand 1 on retinal pigment epithelium during inflammatory conditions","volume":"50","author":"Sugita","year":"2009","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"12","key":"10.1016\/j.ajo.2024.12.028_bib0016","doi-asserted-by":"crossref","first-page":"363","DOI":"10.31083\/j.fbl2812363","article-title":"Biological immune mechanism of retina","volume":"28","author":"Zhu","year":"2023","journal-title":"Front Biosci-Landmark"},{"issue":"1","key":"10.1016\/j.ajo.2024.12.028_bib0017","doi-asserted-by":"crossref","first-page":"20033","DOI":"10.1038\/s41598-024-68401-y","article-title":"Single-cell transcriptomic analysis of retinal immune regulation and blood-retinal barrier function during experimental autoimmune uveitis","volume":"14","author":"Quinn","year":"2024","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.ajo.2024.12.028_bib0018","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1080\/09273948.2019.1582785","article-title":"Intraocular concentrations of cytokines and chemokines in a unique case of nivolumab-induced uveitis","volume":"28","author":"Yoshida","year":"2020","journal-title":"Ocul Immunol Inflamm"},{"issue":"1","key":"10.1016\/j.ajo.2024.12.028_bib0019","doi-asserted-by":"crossref","first-page":"6309","DOI":"10.1038\/s41598-023-33582-5","article-title":"Micro-abnormalities in the retina and choroid induced by anti-CTLA4 treatment","volume":"13","author":"Mukai","year":"2022","journal-title":"Sci Rep-uk"},{"issue":"6","key":"10.1016\/j.ajo.2024.12.028_bib0020","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1080\/09273948.2018.1459733","article-title":"Management of chronic hypotony following bilateral uveitis in a patient treated with pembrolizumab for cutaneous metastatic melanoma","volume":"27","author":"Reid","year":"2019","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.ajo.2024.12.028_bib0021","doi-asserted-by":"crossref","first-page":"944","DOI":"10.3389\/fonc.2019.00944","article-title":"Pembrolizumab induced ocular hypotony with near complete vision loss, interstitial pulmonary fibrosis and arthritis","volume":"9","author":"Nguyen","year":"2019","journal-title":"Front Oncol"},{"issue":"9","key":"10.1016\/j.ajo.2024.12.028_bib0022","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/CJI.0000000000000328","article-title":"Pembrolizumab-related bilateral ocular hypotony, uveitis, cataracts, exudative retinal, and choroidal detachments: an unusual success story","volume":"43","author":"Golash","year":"2020","journal-title":"J Immunother"},{"issue":"8","key":"10.1016\/j.ajo.2024.12.028_bib0023","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1001\/jamaophthalmol.2015.1128","article-title":"Letson AD, Cebulla CM. Bilateral choroidopathy and serous retinal detachments during ipilimumab treatment for cutaneous melanoma","volume":"133","author":"Mantopoulos","year":"2015","journal-title":"Jama Ophthalmol"},{"issue":"12","key":"10.1016\/j.ajo.2024.12.028_bib0024","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1001\/jamaophthalmol.2017.4872","article-title":"Combination ipilimumab and nivolumab for metastatic melanoma associated with ciliochoroidal effusion and exudative retinal detachment","volume":"135","author":"Tsui","year":"2017","journal-title":"Jama Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2024.12.028_bib0025","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1159\/000496682","article-title":"Vogt-Koyanagi-Harada disease-like uveitis during nivolumab (anti-PD-1 antibody) treatment for metastatic cutaneous malignant melanoma","volume":"10","author":"Obata","year":"2019","journal-title":"Case Reports Ophthalmol"},{"issue":"7","key":"10.1016\/j.ajo.2024.12.028_bib0026","doi-asserted-by":"crossref","first-page":"439","DOI":"10.2217\/imt-2019-0206","article-title":"Concurrent Vogt\u2013Koyanagi\u2013Harada disease and impressive response to immune checkpoint blockade in metastatic melanoma","volume":"12","author":"Gambichler","year":"2020","journal-title":"Immunotherapy"},{"issue":"3","key":"10.1016\/j.ajo.2024.12.028_bib0027","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1159\/000520416","article-title":"A case of Vogt-Koyanagi-Harada disease-like uveitis induced by nivolumab and ipilimumab combination therapy","volume":"12","author":"Minami","year":"2021","journal-title":"Case Reports Ophthalmol"},{"issue":"6","key":"10.1016\/j.ajo.2024.12.028_bib0028","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/ced.14640","article-title":"Vogt\u2013Koyanagi\u2013Harada-like syndrome in the setting of combined anti-PD1\/anti-CTLA4 therapy","volume":"46","author":"Godse","year":"2021","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"10.1016\/j.ajo.2024.12.028_bib0029","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s00417-017-3835-2","article-title":"Checkpoint inhibitor-induced uveitis: a case series","volume":"256","author":"Conrady","year":"2018","journal-title":"Graefe's Archive Clin Exp Ophthalmol"},{"key":"10.1016\/j.ajo.2024.12.028_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2020.102454","article-title":"Evolving spectrum of drug-induced uveitis at the era of immune checkpoint inhibitors results from the WHO's pharmacovigilance database","volume":"111","author":"Anquetil","year":"2020","journal-title":"J Autoimmun"},{"issue":"1","key":"10.1016\/j.ajo.2024.12.028_bib0031","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1080\/09273948.2020.1773867","article-title":"Ocular adverse events induced by immune checkpoint inhibitors: a comprehensive pharmacovigilance analysis","volume":"30","author":"Bomze","year":"2022","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.ajo.2024.12.028_bib0032","article-title":"Outcome of nivolumab-induced Vogt\u2013Koyanagi\u2013Harada disease-like uveitis in a patient managed without intravenous methylprednisolone therapy","volume":"2023","author":"Nagai","year":"2023","journal-title":"Case Rep Ophthalmol Med"},{"issue":"8","key":"10.1016\/j.ajo.2024.12.028_bib0033","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1111\/1346-8138.13612","article-title":"Case of acute anterior uveitis and Vogt\u2013Koyanagi\u2013Harada syndrome-like eruptions induced by nivolumab in a melanoma patient","volume":"44","author":"Arai","year":"2017","journal-title":"J Dermatology"},{"issue":"6","key":"10.1016\/j.ajo.2024.12.028_bib0034","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1111\/1346-8138.14273","article-title":"HLA-DRB1\u00d704:05 in two cases of Vogt\u2013Koyanagi\u2013Harada disease-like uveitis developing from an advanced melanoma patient treated by sequential administration of nivolumab and dabrafenib\/trametinib therapy","volume":"45","author":"Fujimura","year":"2018","journal-title":"J Dermatol"},{"issue":"1","key":"10.1016\/j.ajo.2024.12.028_bib0035","doi-asserted-by":"crossref","first-page":"13580","DOI":"10.1038\/s41598-023-40565-z","article-title":"HLA-DRB1\u00d704:05 is involved in the development of Vogt\u2013Koyanagi\u2013Harada disease-like immune-related adverse events in patients receiving immune checkpoint inhibitors","volume":"13","author":"Takeuchi","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.ajo.2024.12.028_bib0036","article-title":"Ocular immune-related adverse events associated with immune checkpoint inhibitors in lung cancer","volume":"12","author":"Zhou","year":"2021","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.ajo.2024.12.028_bib0037","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1080\/09273948.2020.1781902","article-title":"Immune checkpoint inhibitor-associated uveitis: review of treatments and outcomes","volume":"29","author":"Dow","year":"2021","journal-title":"Ocul Immunol Inflamm"},{"issue":"7","key":"10.1016\/j.ajo.2024.12.028_bib0038","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/jamaophthalmol.2019.0970","article-title":"Fundus hypopigmentation and loss of choroidal nevi pigmentation associated with nivolumab","volume":"137","author":"Sophie","year":"2019","journal-title":"Jama Ophthalmol"},{"key":"10.1016\/j.ajo.2024.12.028_bib0039","article-title":"Progressive choroidal thinning (leptochoroid) and fundus depigmentation associated with checkpoint inhibitors","volume":"19","author":"Canestraro","year":"2020","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"2","key":"10.1016\/j.ajo.2024.12.028_bib0040","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41435-022-00168-6","article-title":"Progress in the genetics of uveitis","volume":"23","author":"Huang","year":"2022","journal-title":"Genes Immun"},{"key":"10.1016\/j.ajo.2024.12.028_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajoc.2020.100652","article-title":"Checkpoint inhibitor-induced sarcoid choroidal granulomas","volume":"18","author":"Ung","year":"2020","journal-title":"Am J Ophthalmol Case Reports"},{"issue":"4","key":"10.1016\/j.ajo.2024.12.028_bib0042","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/ICB.0000000000001413","article-title":"Severe multifocal placoid chorioretinitis associated with immune checkpoint inhibitor therapy","volume":"18","author":"Yu","year":"2024","journal-title":"Retin Cases Brief Rep"},{"issue":"10","key":"10.1016\/j.ajo.2024.12.028_bib0043","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1001\/jamaophthalmol.2018.1851","article-title":"Birdshot-like chorioretinopathy associated with pembrolizumab treatment","volume":"136","author":"Acaba-Berrocal","year":"2018","journal-title":"Jama Ophthalmol"},{"key":"10.1016\/j.ajo.2024.12.028_bib0044","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajoc.2022.101351","article-title":"Multiple evanescent white dot syndrome-like reaction associated with ipilimumab and nivolumab immune checkpoint inhibitor therapy for metastasis of choroidal melanoma","volume":"25","author":"Duong","year":"2022","journal-title":"Am J Ophthalmol Case Reports"},{"issue":"4","key":"10.1016\/j.ajo.2024.12.028_bib0045","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1097\/IAE.0000000000000429","article-title":"Paraneoplastic sarcoid-like reactions and the eye","volume":"35","author":"Balasubramaniam","year":"2015","journal-title":"Retina"},{"issue":"8","key":"10.1016\/j.ajo.2024.12.028_bib0046","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jtho.2018.04.031","article-title":"Sarcoidosis-like reactions induced by checkpoint inhibitors","volume":"13","author":"Gkiozos","year":"2018","journal-title":"J Thorac Oncol"},{"issue":"5","key":"10.1016\/j.ajo.2024.12.028_bib0047","doi-asserted-by":"crossref","first-page":"e133","DOI":"10.1016\/j.chest.2015.10.082","article-title":"Nivolumab-induced sarcoid-like granulomatous reaction in a patient with advanced melanoma","volume":"149","author":"Danlos","year":"2016","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.ajo.2024.12.028_bib0048","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1046\/j.1365-2990.2003.00499.x","article-title":"The pathology and pathogenesis of retinal vasculitis","volume":"29","author":"Hughes","year":"2003","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"1","key":"10.1016\/j.ajo.2024.12.028_bib0049","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.oret.2021.04.012","article-title":"The clinical characteristics of noninfectious occlusive retinal vasculitis","volume":"6","author":"Huvard","year":"2022","journal-title":"Ophthalmol Retin"},{"issue":"1","key":"10.1016\/j.ajo.2024.12.028_bib0050","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0165-2478(03)00159-7","article-title":"Serum levels of chemokines correlate with disease activity in patients with retinal vasculitis","volume":"90","author":"Wallace","year":"2003","journal-title":"Immunol Lett"},{"issue":"6","key":"10.1016\/j.ajo.2024.12.028_bib0051","doi-asserted-by":"crossref","first-page":"3338","DOI":"10.4049\/jimmunol.1004019","article-title":"Autoreactive memory CD4+ T lymphocytes that mediate chronic uveitis reside in the bone marrow through STAT3-dependent mechanisms","volume":"187","author":"Oh","year":"2011","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.ajo.2024.12.028_bib0052","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1159\/000507609","article-title":"Retinal vasculitis secondary to durvalumab","volume":"11","author":"Andrade","year":"2020","journal-title":"Case Reports Ophthalmol"},{"key":"10.1016\/j.ajo.2024.12.028_bib0053","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1025125","article-title":"Case report: camrelizumab associated with central retinal vein occlusion","volume":"13","author":"Zhan","year":"2022","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.ajo.2024.12.028_bib0054","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1007\/s10067-018-4177-0","article-title":"Vasculitis associated with immune checkpoint inhibitors\u2014a systematic review","volume":"37","author":"Daxini","year":"2018","journal-title":"Clin Rheumatol"},{"issue":"6","key":"10.1016\/j.ajo.2024.12.028_bib0055","doi-asserted-by":"crossref","first-page":"E970","DOI":"10.1073\/pnas.1616848114","article-title":"Immunoinhibitory checkpoint deficiency in medium and large vessel vasculitis","volume":"114","author":"Zhang","year":"2017","journal-title":"Proc National Acad Sci"},{"issue":"4","key":"10.1016\/j.ajo.2024.12.028_bib0056","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.oret.2019.11.006","article-title":"Clinical and morphological characteristics of anti\u2013programmed death ligand 1\u2013associated retinopathy expanding the spectrum of acute macular neuroretinopathy","volume":"4","author":"Ramtohul","year":"2020","journal-title":"Ophthalmol Retin"},{"issue":"1","key":"10.1016\/j.ajo.2024.12.028_bib0057","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1001\/jamaophthalmol.2018.5191","article-title":"Association of cancer immunotherapy with acute macular neuroretinopathy and diffuse retinal venulitis","volume":"137","author":"Emens","year":"2019","journal-title":"Jama Ophthalmol"},{"issue":"7","key":"10.1016\/j.ajo.2024.12.028_bib0058","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1001\/jamaophthalmol.2022.1327","article-title":"Sudden-onset monocular blurry vision in a young woman","volume":"140","author":"Lains","year":"2022","journal-title":"Jama Ophthalmol"},{"issue":"12","key":"10.1016\/j.ajo.2024.12.028_bib0059","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/j.ophtha.2017.05.038","article-title":"Clinical and morphologic characteristics of MEK inhibitor\u2013associated retinopathy differences from central serous chorioretinopathy","volume":"124","author":"Francis","year":"2017","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.ajo.2024.12.028_bib0060","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/CJI.0b013e31823aa41c","article-title":"Ipilimumab increases activated T cells and enhances humoral immunity in patients with advanced melanoma","volume":"35","author":"Weber","year":"2012","journal-title":"J Immunother"},{"issue":"11","key":"10.1016\/j.ajo.2024.12.028_bib0061","doi-asserted-by":"crossref","first-page":"5783","DOI":"10.1167\/iovs.09-5098","article-title":"Inhibition of B-cell activation by retinal pigment epithelium","volume":"51","author":"Sugita","year":"2010","journal-title":"Investig Opthalmology Vis Sci"},{"issue":"3","key":"10.1016\/j.ajo.2024.12.028_bib0062","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.3390\/ijms24032769","article-title":"Implication of the gut microbiome and microbial-derived metabolites in immune-related adverse events: emergence of novel biomarkers for cancer immunotherapy","volume":"24","author":"Dora","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"7","key":"10.1016\/j.ajo.2024.12.028_bib0063","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.ophtha.2019.01.031","article-title":"Ophthalmic immune-related adverse events of immunotherapy: a single-site case series","volume":"126","author":"Kim","year":"2019","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.ajo.2024.12.028_bib0064","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1097\/ICB.0000000000000882","article-title":"Choroidal neovascularization and chorioretinal atrophy in a patient with melanoma-associated retinopathy after ipilimumab\/nivolumab combination therapy","volume":"15","author":"Elwood","year":"2021","journal-title":"Retin Cases Brief Reports"},{"issue":"1","key":"10.1016\/j.ajo.2024.12.028_bib0065","doi-asserted-by":"crossref","DOI":"10.1136\/bmjophth-2021-000889","article-title":"Autoimmune retinopathy with associated anti-retinal antibodies as a potential immune-related adverse event associated with immunotherapy in patients with advanced cutaneous melanoma: case series and systematic review","volume":"7","author":"Heng","year":"2022","journal-title":"Bmj Open Ophthalmol"},{"key":"10.1016\/j.ajo.2024.12.028_bib0066","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajoc.2023.101849","article-title":"Pigmentary retinopathy associated with immune therapy for advanced cutaneous melanoma","volume":"30","author":"Lin","year":"2023","journal-title":"Am J Ophthalmol Case Reports"},{"issue":"10","key":"10.1016\/j.ajo.2024.12.028_bib0067","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1001\/jamaophthalmol.2016.2944","article-title":"Chorioretinal lesions in a case of melanoma-associated retinopathy treated with pembrolizumab","volume":"134","author":"Roberts","year":"2016","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ajo.2024.12.028_bib0068","doi-asserted-by":"crossref","DOI":"10.2174\/18743641-v17-230308-2023-4","article-title":"Vogt-Koyanagi-Harada-like syndrome and electronegative electroretinogram after nivolumab therapy for metastatic cutaneous melanoma: a case report","volume":"17","author":"Pole","year":"2023","journal-title":"Open Ophthalmol J"},{"issue":"17","key":"10.1016\/j.ajo.2024.12.028_bib0069","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ajo.2024.12.028_bib0070","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejca.2018.10.014","article-title":"Immune-related adverse events predict the therapeutic efficacy of anti\u2013PD-1 antibodies in cancer patients","volume":"109","author":"Rogado","year":"2019","journal-title":"Eur J Cancer"},{"issue":"8","key":"10.1016\/j.ajo.2024.12.028_bib0071","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1080\/08820538.2021.1906916","article-title":"Recurrent episodes with serous retinal detachment and anterior uveitis in a patient using nivolumab (anti -PD-1 antibody) therapy: a case report and 2literature review","volume":"36","author":"Tugan","year":"2021","journal-title":"Semin Ophthalmol"},{"issue":"7","key":"10.1016\/j.ajo.2024.12.028_bib0072","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002119","article-title":"Ocular adverse events in PD-1 and PD-L1 inhibitors","volume":"9","author":"Young","year":"2021","journal-title":"J Immunother Cancer"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939425000066?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939425000066?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T16:10:33Z","timestamp":1742314233000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939425000066"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":72,"alternative-id":["S0002939425000066"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2024.12.028","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pathogenic Mechanisms of Immune Checkpoint Inhibitor (ICI)-Associated Retinal and Choroidal Adverse Reactions","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2024.12.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}